Surufatinib Capsules, a domestic Class 1 innovative oral VEGFR-TKI targeted agent, is the world’s first of its kind to cover both pancreatic and non-pancreatic neuroendocrine tumors.
Authentic
Guarantee
Fast Delivery
Privacy Copyright 2024 @ haiouhealth.com All right reserved SEAGULL HEALTH



